Elevated RAB10 phosphorylation was also observed in patients with PD having LRRK2 mutation sites other than G2019S (29), indicating that RAB10 phosphorylation could be a relevant biomarker of LRRK2 activity and dysfunction in PD patients (25). This evidence concerns the gene RAB10 and Parkinson disease.